Detection, Diagnostics, and Devices Infrastructure (DDDI) Medical Countermeasures Program

Rapid response to CBRN, pandemic influenza and emerging infectious disease threats requires a robust investment in diagnostics and devices across the spectrum of advanced research & development, stockpiling and domestic manufacturing capacity expansion.

DASHBOARD

37
37

EUAs/INDs for BARDA-supported Products

62
62

DDDI MCM Products in Portfolio

FY2021 Investments:
FY2021 Investments:

Influenza + CBRN $47M & COVID-19 $418M

DDDI FY2021 investment was $465 Million, with 47M invested in Influenzas + CBRN products across Advanced Research and Development, Project Bioshield and Pandemic Influenza programs and $418M invested in COVID-19 products

Detection, Diagnostics, and Devices Infrastructure
Medical Countermeasures

BARDA’s Detection, Diagnostics, and Devices Infrastructure Division funds the development of testing and medical device countermeasures, along with select cases for domestic manufacturing capacity, to produce them to address all threats in BARDA’s mission space: CBRN, influenza, and emerging diseases.

These investments are for development of testing systems and medical devices for use across the entire spectrum of use cases, from traditional hospital or central laboratory settings to limited healthcare resource settings, such as outpatient clinics, doctor’s offices, nursing homes, tribal clinics, businesses, temporary healthcare facilities and even homes. DDDI invests in products through-out the product development life cycle, from late-stage research through FDA clearance/Licensure.

The majority of DDDI’s investments are for development of medical countermeasures to diagnose & detect specific infectious diseases such as biothreats, Influenza, or emerging diseases. Others are for improving the quality of casualty care, such as informing the appropriate and effective prescription of antibiotics, estimating the amount of ionizing radiation a casualty has absorbed, or medical devices to alert the potential of an adverse health condition, simplifying collection or processing of patient testing samples, novel respiratory protection devices.
Hear directly from the BARDA DDDI Director on the division’s 2022 priorities.
BARDA Industry Day 2021
Mr. Rodney Wallace B.S., BARDA DDDI Director
Pre-recorded for November 3, 2021 Download Video Transcript

Explore Our Key Initiatives

Working with our partners we are focusing on expanding the US domestic capacity and capability to develop and deploy medical countermeasures to diagnose and detect infectious disease threats.

Select an initiative to learn more:
Rapid Test Availability in Emerging Disease Outbreaks')
Moving Testing Closer
to the Patient
Moving Testing Closer
Rapid Test Availability in Emerging Disease Outbreaks
Domestic Test Manufacturing Capacity Expansion
Domestic Test Manufacturing

Explore Our Key Initiatives

Working with our partners we are focusing on expanding the US domestic capacity and capability to develop and deploy medical countermeasures to diagnose and detect infectious disease threats.

Select a principle to learn more:
Moving Testing Closer
  • Home Tests
  • Limited Resource Testing
Rapid Test Availability in Emerging Disease Outbreaks')
  • Threat Agnostic Testing
  • Fast Threat Specific Test Development/Manufacturing
Domestic Test Manufacturing Capacity Expansion
  • Onshoring and expanding domestic diagnostic manufacturing capacity.
BARDA Programs

Driving Innovation and Expansion in the Field

Home-use
Molecular Tests

Sample Collection
Technologies

Appropriate
use of Antibiotics

Respiratory
Protective Devices

BARDA’s newest COVID-19 Partnership Opportunity

Area of Interest (AOI) 7.7.5 Screening Tests at Point of Care (2-minute Time to Result)

Under BARDA’s Broad Agency Announcement, we are seeking proposals for the development, FDA Emergency Use Authorization (EUA) and FDA 510k clearance of a low-cost, portable, easy-to-use, Point of Care, In-Vitro diagnostic test to detect COVID-19 disease. Tests should analyze specimens that can be easily collected in CLIA-waived settings and provide results in 2 minutes or less.

Learn more about this opportunity

BARDA JUMP-STARTED COVID-19 TESTS

BARDA scientists started working with private-sector partners in January 2020, days after the novel coronavirus was first reported.

BARDA continues to support test development and has expanded support of programs that increase testing speed and capacity for lab tests, as well as broaden access to testing by developing point-of-care and home-use platforms.

Strategic Priorities

Investing in innovative diagnostics and devices to detect or prevent the medical consequences that result from pandemic influenza and emerging infectious diseases. Explore the investment of each of our key teams and product areas

MCM Portfolio
BARDA’s COVID-19 Diagnostic and Device Portfolio
Explore BARDA's expanding COVID-19 medical countermeasure portfolio to learn about the exciting products in the pipeline

Reports and References